Abstract 284P
Background
Head and neck squamous cell carcinoma (HNSCC) was the 8th most common cancer worldwide in 2018. Incidence and mortality rates of HNSCC vary by geographical location, and Taiwan has one of the world’s highest incidence rates of oral cancers. Metronomic chemotherapy inhibits tumor growth by continuous administration of lower-dose chemotherapy. Our study aims to demonstrate the outcomes of metronomic chemotherapy with tegafur-uracil (UFUR) in locally advanced HNSCC.
Methods
This is a retrospective study. We included 240 patients with locally advanced (stage III or non-distant metastatic stage IV) HNSCC. Operable patients without post-operational high-risk features were excluded. High-risk features were positive surgical margins, extranodal extension (ENE), perineural invasion (PNI) or lymphovascular invasion (LVI). After standard treatment, 96 patients were further treated with metronomic UFUR and 144 patients were not. The last date of follow-up of this study was 5 April 2020.
Results
There were also no statistical differences between both groups in gender, clinical cancer stage and primary treatment choice. However, there were more hypopharynx cancers in UFUR group and more oral cavity cancers in control group. There were significantly more high-grade features, including LVI (P=0.018), ENE (P<0.001), and positive margin (P=0.025) in UFUR group. The median follow-up duration was 31.16 months (range: 3.80-87.38). The overall survival was not reached in the UFUR group and 54.1 months in control group (p =0.008). For disease-free survival (DFS), the median DFS was 54.5 months (95% CI=40.7-not reached) in the UFUR group and 34.4 months (95% CI=25.2-not reached) in the control group (p =0.03). For distant metastasis-free survival, both groups were not reached (p =0.02). In both groups, primary local recurrence was the most common reason of treatment failure. Overall prevalence of adverse event of UFUR was very low and the most common adverse events were low-grade nausea (3.8%), vomiting (3.3%), neutropenia (1.7%) and mucositis (2.1%).
Conclusions
In patients with high-risk and unresectable locally advanced HNSCC, adding UFUR as a metronomic chemotherapy after either curative surgery with adjuvant chemoradiotherapy or definitive concurrent chemoradiotherapy was found to significantly improve OS, DFS and DMFS rates with tolerable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session